Ferroptosis, an iron-driven lipid oxidation death pathway, shapes liver injury, fibrosis, and cancer, offering dual therapeutic potential to protect hepatocytes or selectively eliminate resistant tumor cells.

A newly identified molecular signature in polycythemia vera improves prediction of disease progression, enabling biologically informed risk stratification, personalized monitoring, and earlier intervention for high-risk patients.

Medicaid expansion improves breast cancer outcomes by increasing early-stage diagnoses, reducing late-stage disease, narrowing racial disparities, lowering mortality, and stabilizing health systems through earlier, affordable access to care.

New research clarifies rare mRNA vaccine–associated myocarditis arises from brief innate immune overactivation, guiding safer dosing, monitoring strategies, and next-generation vaccine design while preserving public confidence.

Wider use of targeted cancer drugs and immunotherapies is elevating ocular toxicity risk, requiring early recognition, multidisciplinary coordination, and proactive monitoring to protect vision without compromising cancer control.

Real-world data show about one-quarter of lupus patients achieve six-month remission with anifrolumab, supporting earlier targeted therapy, steroid reduction, and evolving care pathways for systemic lupus erythematosus.

Research links sleep disruption to microglial activation, reframing insomnia as neuro-immune stress that may drive inflammation, cognitive fog, mood symptoms, and long-term brain vulnerability.

Long-term data from the ACTIVE trial suggest speed-based cognitive training with boosters may lower dementia risk, supporting scalable, nonpharmacologic prevention strategies for at-risk older adults.

FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.

FDA-cleared CTA software creates patient-specific 3D cardiac conduction maps for planning and live guidance, aiming to reduce conduction injury, pacing complications, and procedural uncertainty.